Prescription medicine
Somapacitan Brand names: Sogroya
Somapacitan (Sogroya) is a prescription medicine. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the somapacitan FDA label on DailyMed (effective February 25, 2026); every somapacitan label on DailyMed.
Highlights of the record
FDA label of February 25, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageSOGROYA is indicated for the treatment of pediatric patients aged 2.5 years and older with:
Growth failure due to inadequate secretion of endogenous growth hormone (GH).
Forms and strengths
- 3.3 mg/ml
- 6.7 mg/ml
- 10 mg/ml
Injection (solution).
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 156 through July 30, 2026
What is somapacitan used for?
From the label: indications and usageSOGROYA is indicated for the treatment of pediatric patients aged 2.5 years and older with:
Growth failure due to inadequate secretion of endogenous growth hormone (GH).
Short stature born small for gestational age (SGA) and with no catch-up growth by 2 years of age.
Growth failure associated with Noonan syndrome (NS).
Idiopathic Short Stature (ISS). SOGROYA is indicated for the replacement of endogenous GH in adults with growth hormone deficiency (GHD). SOGROYA is a human growth hormone analog indicated for: Pediatric Patients: Treatment of pediatric patients aged 2.5 years and older with:
Growth failure due to inadequate secretion of endogenous growth hormone (GH). […]
Source: FDA drug label (SOGROYA), Novo Nordisk, effective February 25, 2026 (SPL set eadd03b4-adc3-4b88-8a24-9d205c5b85aa), via openFDA; the full label on DailyMed
Is there a generic for somapacitan (Sogroya)?
No generic somapacitan is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the somapacitan label say about other medicines?
The somapacitan label names 4 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Corticotropin | warnings and precautions | Patients receiving somatropin therapy who have or are at risk for corticotropin deficiency may be at risk for reduced serum cortisol levels and/or unmasking of central (secondary) hypoadrenalism. |
| Cortisone | drug interactions | Replacement Glucocorticoid Treatment Clinical Impact: Microsomal enzyme 11β-hydroxysteroid dehydrogenase type 1 (11βHSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. GH inhibits 11βHSD-1. … following initiation of SOGROYA [see Warnings and Precautions ()]. Examples: Cortisone acetate and prednisone may be affected more than others because conversion of these drugs to their biologically active metabolites … |
| Prednisone | drug interactions | Replacement Glucocorticoid Treatment Clinical Impact: Microsomal enzyme 11β-hydroxysteroid dehydrogenase type 1 (11βHSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. GH inhibits 11βHSD-1. … SOGROYA [see Warnings and Precautions ()]. Examples: Cortisone acetate and prednisone may be affected more than others because conversion of these drugs to their biologically active metabolites is dependent on the … |
| Somatropin | contraindications | Systemic hypersensitivity reactions have been reported postmarketing with somatropin [see Warnings and Precautions ( 5.2 )]. |
Source: FDA drug label (SOGROYA), Novo Nordisk, effective February 25, 2026 (SPL set eadd03b4-adc3-4b88-8a24-9d205c5b85aa), via openFDA; the full label on DailyMed
What do FAERS reports show for somapacitan?
The FDA Adverse Event Reporting System holds 156 reports that list somapacitan among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 10 are coded as a death and 42 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Somapacitan side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other